2 209

Cited 0 times in

High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.

DC FieldValueLanguage
dc.contributor.author금웅섭-
dc.contributor.author성진실-
dc.contributor.author송시영-
dc.contributor.author윤홍인-
dc.contributor.author정윤선-
dc.contributor.author장지석-
dc.date.accessioned2014-12-19T16:58:04Z-
dc.date.available2014-12-19T16:58:04Z-
dc.date.issued2012-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/90530-
dc.description.abstractPURPOSE: To improve poor therapeutic outcome of current practice of chemoradiotherapy (CRT), high-dose helical tomotherapy (HT) with concurrent full-dose chemotherapy has been performed on patients with locally advanced pancreatic cancer (LAPC), and the results were analyzed. METHODS AND MATERIALS: We retrospectively reviewed 39 patients with LAPC treated with radiotherapy using HT (median, 58.4 Gy; range, 50.8-59.9 Gy) and concomitant chemotherapy between 2006 and 2009. Radiotherapy was directed to the primary tumor with a 0.5-cm margin without prophylactic nodal coverage. Twenty-nine patients (79%) received full-dose (1000 mg/m(2)) gemcitabine-based chemotherapy during HT. After completion of CRT, maintenance chemotherapy was administered to 37 patients (95%). RESULTS: The median follow-up was 15.5 months (range, 3.4-43.9) for the entire cohort, and 22.5 months (range, 12.0-43.9) for the surviving patients. The 1- and 2-year local progression-free survival rates were 82.1% and 77.3%, respectively. Eight patients (21%) were converted to resectable status, including 1 with a pathological complete response. The median overall survival and progression-free survival were 21.2 and 14.0 months, respectively. Acute toxicities were acceptable with no gastrointestinal (GI) toxicity higher than Grade 3. Severe late GI toxicity (≥ Grade 3) occurred in 10 patients (26%); 1 treatment-related death from GI bleeding was observed. CONCLUSION: High-dose helical tomotherapy with concurrent full-dose chemotherapy resulted in improved local control and long-term survival in patients with LAPC. Future studies are needed to widen the therapeutic window by minimizing late GI toxicity.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHChemoradiotherapy/adverse effects-
dc.subject.MESHChemoradiotherapy/methods*-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/analogs & derivatives-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDrug Combinations-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOxonic Acid/administration & dosage-
dc.subject.MESHPancreatic Neoplasms/mortality-
dc.subject.MESHPancreatic Neoplasms/pathology-
dc.subject.MESHPancreatic Neoplasms/therapy*-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRadiotherapy, Intensity-Modulated/adverse effects-
dc.subject.MESHRadiotherapy, Intensity-Modulated/methods*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTegafur/administration & dosage-
dc.subject.MESHTreatment Outcome-
dc.titleHigh-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorMichael L.C. Wang-
dc.contributor.googleauthorWoong Sub Koom-
dc.contributor.googleauthorHong In Yoon-
dc.contributor.googleauthorYoonsun Chung-
dc.contributor.googleauthorSi Young Song-
dc.contributor.googleauthorJinsil Seong-
dc.identifier.doi22285669-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00273-
dc.contributor.localIdA01956-
dc.contributor.localIdA02035-
dc.contributor.localIdA03678-
dc.contributor.localIdA04777-
dc.contributor.localIdA04658-
dc.relation.journalcodeJ01157-
dc.identifier.eissn1879-355X-
dc.identifier.pmid22285669-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0360301611034584-
dc.subject.keywordLocally advanced pancreatic cancer-
dc.subject.keywordRadiotherapy-
dc.subject.keywordHelical tomotherapy-
dc.subject.keywordPatterns of failure-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.alternativeNameYoon, Hong In-
dc.contributor.alternativeNameChung, Yoon Sun-
dc.contributor.affiliatedAuthorKoom, Woong Sub-
dc.contributor.affiliatedAuthorSeong, Jin Sil-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.contributor.affiliatedAuthorChung, Yoon Sun-
dc.contributor.affiliatedAuthorYoon, Hong In-
dc.citation.volume83-
dc.citation.number5-
dc.citation.startPage1448-
dc.citation.endPage1454-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.83(5) : 1448-1454, 2012-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.